Biogen, Inc.
https://www.biogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biogen, Inc.
Finance Watch: Summer Ends, But Fundraising Heats Up For ArsenalBio, Vaxcyte
ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering. Also, Circle Pharma closed a $90m series D round and Jazz priced an $850m note sale, but IN8bio revealed a prioritization plan and job cuts.
News We’re Watching: $1B Judgement Against J&J; Recalls For Abbott, Baxter, More; Karl Storz Announces Fujifilm Partnership
This week, a Delaware court awarded Auris Health shareholders $1bn in a lawsuit against Johnson & Johnson; Abbott recalled some FreeStyle Libre 3 sensors; and McKesson purchased a controlling interest in a Florida cancer care chain.
Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain
The company said that while its drug did not achieve statistical significance on any endpoints in the Alzheimer’s study, improvements favoring fosgonimeton showed potential for HGF modulation.
Biogen’s Higher-Dose Spinraza Shows Better Efficacy, But Franchise Stands To Lose Market Share
The higher-dose version of Biogen’s SMA drug showed better efficacy than the approved 12mg dose, which could help it maintain a market foothold, but competitors are likely to overtake it.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Biogen Idec
- Convergence Pharmaceuticals Ltd
- Nightstar Therapeutics plc
- Stromedix, Inc.
- Syntonix Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice